Clinical Trial Update: Lancovutide (Moli1901) Inhalation Solution Study in Adolescents and Adults With Cystic Fibrosis [Phase 2]

View source ↗

Summary

Phase 2 trial of Lancovutide (Moli1901) inhalation solution in adolescents and adults with cystic fibrosis has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cystic Fibrosis

Drugs mentioned

• Lancovutide (Moli1901) Inhalation Solution (Lancovutide)

Snippet

Sponsor: AOP Orphan Pharmaceuticals AG | Conditions: Cystic Fibrosis | Phase 2 | Status: COMPLETED